MOSCOW Dec 19 Russian state technology firm
Rusnano, alongside a group of investors, is investing $93
million in three U.S.-based pharmaceutical firms to develop
drugs to treat illnesses such as epilepsy, the investors said on
Rusnano is making the investment with U.S. venture capital
fund Domain Associates and other investors. Rusnano partnered
with Domain in March with plans to invest around $760 million in
U.S. healthcare and parmaceutical firms to bring new drugs to
the Russian market.
The three companies receiving investments - Marinus
Pharmaceuticals, Lithera and Regado Biosciences - are portfolio
companies of Domain and the investments will be used to register
medications and undertake further clinical trials in the U.S.
and Russia, the companies said.
Marinus is developing a drug for the treatment of epilepsy,
Lithera works on products for aesthetic medicine and
ophthalmology and Regado is developing antithrombotic products.